# US 2013/0295075 A1 · Compositions and methods of treating glaucoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295075 A1
- Document ID: US20130295075A1
- Status: Published application
- Kind: A1
- Application number: 13/887,217
- Filed: 2013-05-03
- Published: 2013-11-07
- Earliest claimed: 2012-05-03
- Assignees: Orasis
- Applicants: Orasis
- Inventors: Richard A. Hill
- Web page: https://patentgrep.com/patent/US20130295075A1

## CPC

- G01N 33/5088: {of vertebrates}
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/665: having oxygen as a ring hetero atom, e.g. fosfomycin
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 38/45: Transferases (2)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided.

## Claims

### Claim 1

A method of lowering intraocular pressure comprising administering a therapeutically effective amount of an amphipathic compound or pharmaceutically acceptable derivative thereof to a subject in need of such treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amphipathic compound comprises ascorbic acid or a derivative, salt or hydrate thereof

### Claim 3 (depends on 1)

The method of claim 1, wherein the amphipathic compound comprises phosphorylated ascorbic acid or derivative, salt or hydrate thereof

### Claim 4 (depends on 3)

The method of claim 3, wherein the compound comprises a phospholipid.

### Claim 5 (depends on 3)

The method of claim 3, wherein the compound comprises micelles.

### Claim 6 (depends on 3)

The method of claim 3, wherein the compound is configured to form a micelle after administering the compound to the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amphipathic compound comprises glycolipid comprising ascorbic acid or derivative, salt, or hydrate thereof

### Claim 8

A method of lowering intraocular pressure comprising administering a therapeutically effective amount of an enzyme or enzymatically active fragment thereof having an enzymatic activity of forming an amphipathic compound or pharmaceutically acceptable derivative thereof to a subject in need of such treatment.

### Claim 9 (depends on 8)

The method of claim 8, wherein the enzymatic activity is a kinase activity.

### Claim 10 (depends on 8)

The method of claim 8, wherein the enzymatic activity is an esterase activity.

### Claim 11 (depends on 8)

The method of claim 8, wherein the enzyme or enzymatically active fragment thereof is delivered by administering a nucleic acid that encodes for the enzyme or enzymatically active agent.

### Claim 12

A method of maintaining a target intraocular pressure, comprising:
measuring a baseline intraocular pressure of a subject;
determining the target intraocular pressure for the subject;
selecting a first therapeutic compound which generally decreases intraocular pressure by an amount about the difference between the baseline intraocular pressure and the target intraocular pressure;
administering the first therapeutic compound;
measuring the intraocular pressure of the subject after administration of the compound;
selecting a second therapeutic compound which decreases the intraocular pressure by an amount different than that of the first therapeutic compound if the intraocular pressure after administration is not about the target intraocular pressure; and
administering the second therapeutic compound.

### Claim 13 (depends on 12)

The method of claim 12, wherein the therapeutic compound is selected from the group consisting of phosphorylated ascorbic acid, phosphorylated ascorbic acid derivative, ascorbic acid containing phospholipid, an ascorbic acid derivative containing phospholipid, an ascorbic acid containing glycolipid, and an ascorbic acid derivative containing glycolipid.

### Claim 14 (depends on 12)

The method of claim 12, wherein the therapeutic compound is an amphipathic compound which increases transport of aqueous humor through a cell membrane.

### Claim 15

A drug screening method comprising:
preparing a donor eye tissue;
introducing fluid into an anterior segment of the donor eye tissue;
introducing a candidate therapeutic molecule into the anterior segment of the donor eye tissue; and
determining a measurement related to the introduction of the candidate therapeutic molecule into the anterior segment of the donor eye tissue.

### Claim 16 (depends on 15)

The method of claim 15, wherein determining a measurement related to the introduction of the candidate therapeutic molecule into the anterior segment of the donor eye tissue comprises measuring an amount or a rate of uptake of the candidate therapeutic molecule into the donor eye tissue.

### Claim 17 (depends on 15)

The method of claim 15, further comprising:
determining a baseline measurement after introducing fluid into the anterior segment of the donor eye tissue;
determining a second measurement after introducing the candidate therapeutic molecule into the anterior segment of the donor eye tissue; and
determining the change in the baseline measurement.

### Claim 18 (depends on 17)

The method of claim 17, wherein the baseline measurement is the rate of outflow from the anterior segment of the eye and the second measurement is the rate of outflow from the anterior segment of the eye.

### Claim 19 (depends on 17)

The method of claim 17, wherein the baseline measurement is the pressure maintained in the anterior segment and the second measurement is the pressure maintained in the anterior segment.
